Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simeprevir
- Development stage
- Phase 4
- Lead developer
- Janssen Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Simeprevir is an orally administered, direct-acting antiviral drug used in combination with other agents for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotypes 1 and 4. It functions as a highly specific inhibitor of the HCV NS3/4A serine protease, an enzyme essential for viral replication and maturation. By blocking this protease, simeprevir prevents cleavage of the HCV polyprotein into functional viral proteins, thereby inhibiting viral replication. Simeprevir is typically used alongside peginterferon alfa and ribavirin or with sofosbuvir in adults with compensated liver disease (including cirrhosis), both in treatment-naive patients and those who have failed previous therapy. The drug was developed by Janssen (a Johnson & Johnson company) and was marketed under the brand name Olysio; however, it has been discontinued in several markets including the United States[2][3][5][6].
- Brand names
- Olysio
- Other names
- simeprevir sodium
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on simeprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simeprevir.